Gastric cancer is still a major health problem worldwide due to its frequency, poor prognosis and limited treatment options. To study the inhibitory effect of nuclear transcription factor kappa B(NF-κB) antisense oligodeoxynucleotide(ASODN) on the growth and tumorgenesis of human gastric cancer, we synthesis and transfect ASODN of NF-κB/P65 to gastric cancer cell line. The effect of ASODN of NF-κB/P65 on the proliferation of gastric cancer cells was measured by MTT method. The subcutaneous xenograft model of human gastric cancer was established in nude mice and the tumor growth curve was observed. The cell proliferation was significantly inhibited in P65 ASODN transfected group in vitro (P<0.05). In vivo, tumor formation test showed that the tumor volume in nude mice in ASODN group was obviously smaller than in other groups (P<0.05), the apoptosis index (AI) was significantly higher (P<0.001).
INTRODUCTION
NF-κB is activated by a variety of cancer-promoting agents [1] . Recent studies showed that as a multifunctional factor, NF-κB involved in a variety of physiological and pathological processes such as immunity, inflammation, gene expression, cancer cell migration invasion, cell apoptosis and proliferation [2] [3] [4] [5] [6] .The mechanism of NF-κB activation in tumor cells is not well elucidated, but it is apparently complex and varies in different tumor types [7] . NF-κB constitutive activation was identified in some cancer cells such as breast cancer, liver cancer, prostate cancer, pancreatic cancer, and gastric cancer [8] . Also, we have previously shown that there exists NF-κB constitutive activation in gastric cancer cell [9, 10] . Antisense reagents and technology have developed as extraordinarily useful tools for analysis of gene function. The capacity of antisense to reduce expression of RNA has led to the concept of using antisense molecules as drugs to treat cancer. behalf of all your co-authors, you are prepared to accept this condition should your paper be published. You may also use this text box for any additional comments about your submission. (ASOs) inhibit translation or induce degradation of complementary target RNA, and both Phase I and Phase II trials such as antisense anti-IGF-I [11] , antisense oligonucleotide GTI-2040 [12] , antisense oligonucleotide ISIS 5132 [13] are either completed or in progress. ASOs have proved their efficacy as targeted therapy in preclinical studies, have been well tolerated and able to modulate target protein expression in clinical studies [14, 15] . Here we examined the impact that antisense oligonucleotide NF-κB on cell proliferation and tumorgenesis of gastric cancer in nude mice. inactivated fetal bovine serum, 2mM L-glutamine, 100U/ml penicillin, and 100 U/ml streptomycin at 37 °C in a humidified atmosphere with 5% CO 2 .
Synthesis of antisense oligonucleotide
P65 antisense oligonucleotide and misantisense oligonucleotides (MSODN)sequence was from the literature [16] . Antisense sequence: 5' GGG GAA CAG TTC GTC CAT GGC 3', target sequence: 5' GCC ATG GAC GAA CTG TTC CCC 3', missense sequence: 5' GTA CGC GGT GAA GCT GCG ATC 3'. According to Genbank, ASODN and MSODN do not match with any known gene. They were synthesized by Takara Biotechnology Co., Ltd (Dalian, China) with phosphorathioate oligonucleotide technology followed by HPLC purification.
Transfection of human gastric cancer cell
Cells would be 90% confluent at the time of transfection, the liposome was respectively mixed with antisense and missense oligonucleotides in serum-free medium in accordance with DOTAP Liposomal Transfection Reagent(Roche, Swiss)
instructions to form liposome-oligonucleotide complexes, which were then added into culture plate. The final concentration of oligonucleotide was 160nmolL -1 .
Seventy-two hours after transfection, cells were harvested for Western Blot, cell immunofluorescence.
MTT examination
The cell proliferating activity was measured by MTT method. During logarithmic PMSF and 1mM DTT) and incubated on ice for 30 minutes, and stirred discontinuously every 10 minutes, then centrifugated at 14000 rpm for 15 minutes, the supernatant nuclear extract was collected. All proteins were stored at -80℃. Protein concentration was determined by BCA kit (Pierce Biotechnology Inc, USA).
SDS-PAGE and Western blot analysis
The nuclear extracts were boiled for 10 min, resolved by SDS-PAGE on an 10%
polyacrylamide gel, and blotted onto nitrocellulose membrane.The membranes were 
Apoptosis detection by TUNEL assay
The reagent kit for apoptosis detection, TdT-FragEL DNA fragmentation detection kit was bought from ONCOGENE. Test procedures consisting of the following sections were provided in the brochure of the kit. Tumor tissues were fixed in 4%
formaldehyde, dehydrated with gradient ethanol, and embedded in paraffin.
Paraffin-embedded tissue samples were cut at 4 μm and examined on a coated slide glass. The specimens were deparaffinized and hydrated gradually, and rinsed with with TUNEL staining in five 400×sights served as apoptosis index (AI).
HE staining and MVD detection
MVD was detected by HE staining and counted according to Weidner method. Areas of highest neovascularization were found by scanning the tumor sections at low power (×100 total magnification).After the area of highest neovascularization was identified, individual microvessel counts were made on a ×200 field. Any highlighted endothelial cell or endothelial cell cluster clearly separate from adjacent microvessels, tumor cells, and other connective tissue elements was considered a single, countable microvessel.
Statistical analysis
The Statistical Package for the Social Science (SPSS) for Microsoft Windows 11.0 was used to complete the analysis of the collected data. All data were expressed as means ± SEM. The means of the different groups were compared using one-way analysis of variance (ANOVA) test. Significant differences were accepted when P<0.05.
RESULTS

ASODN inhibits P65 expression
To determine the effect of ASODN on expression of P65 in gastric cancer cells, we transfected SGC-7901 gastric cancer cells with P65 ASODN. Simultaneously, P65
MSODN as a control. We observed the protein expression of p65 by Western blot analysis. The results showed that the expression of P65 was lower in the ASODN groups than the control groups (P<0.001, Fig 1) . There is no difference among the control groups. 
P65 ASODN inhibits SGC
P65 ASODN suppresses gastric tumor growth in vivo
Because it showed that P65 ASODN has a significant inhibitory effect on the growth of gastric cancer cells in vitro, we next studied the effect of ASODN on tumor growth in vivo. For this, we injected gastric cancer cell transfected by P65 ASODN into nude mice. We periodically monitored the growth of tumor for 24 days. In the P65 ASODN group, the tumor volume is smaller than that in P65 MSODN-treated mice as reflected in Fig. 3 
P65 ASODN reduce the microvessel density(MVD) and induce apoptosis in vivo
At the endpoint, mice were sacrificed and examined for angiogensis in tumor by MVD analysis and cell apoptosis by TUNEL. MVD in the P65 ASODN group was reduced significantly (Fig. 4A, left 
DISCUSSION
In 1986, Baltimore first discovered transcription factor nuclear (NF-κB) in mature B cell nucleus [17] . It was one of the nuclear proteins, which bind with DNA enhancer of immunoglobulin κ light chain. In mammalian cells, it was a kind of dimeric protein complex, composed of homodimers and heterodimers derived from five distinct subunits, including NF-κB1 (p50), NF-κB2 (p52), RelA (p65), Rel B, and c-Rel. P65
contains transcription activating area, and participates in original regulation of gene transcription. Simultaneously, p65 facilitates the combination of p50 with DNA. All family members share a highly conserved Rel homology domain (RHD, ~300aa) responsible for DNA binding, dimerization domain, and interaction with IκBs, the intracellular inhibitor of NF-κB [18, 19] . In most quiescent normal cells, the majority of NF-κB complexes are kept predominantly as an inactive form cytoplasmic and in an inactive form by binding to a family of inhibitory proteins, the IκBs. Many divergent extracellular stimuli including proinflammatory cytokines such as TNF-α, interleukin-1, lipopolysaccharide (LPS), double-stranded RNA, and physical and chemical stresses can induce rapid phosphorylation and degradation of IκB, allowing nuclear translocation of NF-κB [20] . This process is called activation of NF-κB. The signaling pathways involved in NF-κB constitutive activation remain largely unknown. Mechanism of constitutive activation of NF-κB may be involved in activation of tyrosine kinase, NIK, and IKK [21] . NF-κB is involved in cancer development, modulating NF-κB activation pathways has important implications in cancer prevention and therapy. Due to the complexity of NF-κB roles in different cancers, careful evaluation of NF-κB in each cancer type is crucial in this regard.
More cancer cell-specific NF-κB inhibiting means are desired for improving anticancer efficacy and reducing systemic toxicity. In this study, it was suggested that P65 ASODN could inhibit gastric cancer cell proliferation, it maybe related to the decreased expression of P65. Many cell cyclin gene expression is NF-κB-dependent [22] . The best explored link between NF-κB activation and cell cycle 10 / 22 progression involves cyclin D1, a cyclin which is expressed relatively early in the cell cycle and which is crucial to commitment to DNA synthesis. Experiments in many cell types now indicate that NF-κB acts through increasing the abundance of cyclin D1 and thus the activity of the cyclin D1 kinase holoenzyme complex. The role of NF-κB factors in controlling the cell cycle and cyclin D1 has been well shown in investigations that used the IκB "super repressor" (IκB-SR), to inhibit NF-κB activity.
IκB-SR effectively blocks the serum-induced increase in nuclear NF-κB DNA binding activity in mouse embryo fibroblasts and delays S-phase entry when the cells are growing synchronously [23] . The regulator of cell-cycle progression cyclin D1 is upregulated in a variety of cancer cells by mechanisms involving mainly transcriptional activation. Analysis of the human cyclin D1 promoterhas revealed the presence of two κB sites located at -840 and -33, designated κB1 and κB2,
respectively, and mutational analysis demonstrated that p50/p65 binding to the -33 κB2 site was important for cyclin D1 transcriptional regulation during proliferation induced by serum or growth factors [24] .
And also in vivo, we found P65 ASODN inhibited tumor growth which lead to apoptosis increasing and angiogensis reducing. In vitro and in vivo, both liposome only and MSODN can also inhibited gastric cancer cells proliferation and inhibited tumorgenesis, which related to slight toxicity of liposome, there is no statistic difference. It was well known that tumor angiogenesis is dependent on many proinflammatory cytokines and growth factors such as IL-8, TNF-α and VEGF.
NF-κB plays a pivotal role in secreting the angiogenesis factors [25, 26] . Constitutive NF-κB activation in cancer cells also triggers autocrine of angiogenic chemokines, and NF-κB inhibition substantially suppresses tumor growth and angiogenesis [27] .
Previously, there reported NF-κB-mediated IL-8 and angiogenin expression was involved in this process [28] . In this experiment, we noticed that P65 ASODN as inhibitor of NF-κB leads to an decrease in tumor angiogenesis in nude mice.
The evidence that cancer development is a complex and multistep process, characterized by alterations of genes involved in the regulation of proliferation, apoptosis and angiogenesis, has led to development of new therapeutic strategies
based on the use of agents able to selectively inhibit key molecules of these pathways.
Although these agents have shown considerable promise for antitumoral therapy, treatment with ASODN used as single agent does not seem particularly promising because of the multigenic alterations of tumors.
Transcription factors have potential as targets for an individualized therapeutic approach to cancer [29] . Hopefully, in the next few years several NF-κB inhibitors that can increase the therapeutic efficiency of chemotherapy and radiotherapy will be successfully employed in treatment of gastric cancer patients.
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